It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Salt Lake City, United States:
Today, Xlear Inc. filed the company’s response to a Department of Justice lawsuit alleging violations of the Federal Trade Commission Act, among other allegations. The company denied all the Government’s allegations and leveled a series of affirmative defenses at the Government, including violations of Xlear’s First Amendment right to free speech. Nathan Jones, Xlear’s CEO, issued this statement regarding Xlear’s Response:
The United States faces an already raging pandemic and yet another new, wildfire Omicron variant, which studies show is more transmissible, vaccine resistant and as severe as other strains. As a result, across the nation new cases are spiking and breaking records; hospitals are once again overflowing; schools are closing again; not only are we seeing breakthrough infections—we are facing reinfections; the NFL and the NHL have been forced to postpone games; and, there is a real risk that our lives and economy will once again have to close. It’s another COVID-Christmas in America. The nation’s vaccine-only strategy is failing.
Despite this, the Federal Government continues to refuse to even discuss or consider other possible countermeasures—even though they are backed by sound science.
An in-vitro study done collaboratively by Utah State University and Northwestern University finds Xlear components (grapefruit seed extract and xylitol) significantly eliminates SARS-CoV-2, the virus that causes COVID-19
Updates
December 2021: Xlear Files Legal Response to Government’s Lawsuit
September 2021: Xlear Nasal Spray Company Pushes CDC, FDA to Accept Its Claims to Help Treat COVID
May 2021: Xlear CEO explains Xlear Nasal Spray’s lasting role against COVID-19
According to Nathan Jones, CEO of Xlear:
With all of the research supporting Xlear, we have applied for an “emergency use authorization” with the FDA. We have five in vitro studies showing how our nasal spray affects the SARS-CoV-2 virus, we have a good understanding of the method of action of how the xylitol blocks adhesion, we have small in-human trials of COVD-19 patients showing great results and we have two larger trials underway right now.
March 2021: Xlear Submits COVID-19 Pre-Emergency Use Authorization Request with FDA Regarding Use of Xlear Nasal Spray in Help in Combating SARS-CoV-2
They hide working treatments while forcing non-working harmful 'vaccines' , that are still in clinical trials till 2023
Ivermectin is an FDA-approved broad-spectrum antiparasitic agent with demonstrated antiviral activity against a number of DNA and RNA viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite this promise, the antiviral activity of ivermectin has not been consistently proven in vivo. While ivermectin's activity against SARS-CoV-2 is currently under investigation in patients, insufficient emphasis has been placed on formulation challenges. Here, we discuss challenges surrounding the use of ivermectin in the context of coronavirus disease-19 (COVID-19) and how novel formulations employing micro- and nanotechnologies may address these concerns.
originally posted by: Dae
a reply to: puzzled2
As soon as this study came out I bought me a bottle!